Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma

Title: Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma

Volume: 7 Issue: 6

Author(s): Maurizio Zangari, Federica Cavallo and Guido Tricot

Affiliation:

Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies

Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.

Cite this article as:

Zangari Maurizio, Cavallo Federica and Tricot Guido, Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116838